0L49 Stock Overview A biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
SCYNEXIS, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for SCYNEXIS Historical stock prices Current Share Price US$1.00 52 Week High US$3.07 52 Week Low US$0.98 Beta 1.52 1 Month Change -26.03% 3 Month Change -35.03% 1 Year Change -52.89% 3 Year Change -83.98% 5 Year Change n/a Change since IPO -94.74%
Recent News & Updates
SCYNEXIS, Inc. Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections Dec 18
SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Nov 08 SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Nov 07
SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024 Oct 04
Second quarter 2024 earnings released: US$0.30 loss per share (vs US$2.56 profit in 2Q 2023) Aug 09
First quarter 2024 earnings released: EPS: US$0.009 (vs US$0.71 loss in 1Q 2023) May 09 See more updates
SCYNEXIS, Inc. Initiates Dosing in Phase 1 Trial of SCY-247, a Second-Generation Fungerp Candidate for Invasive Fungal Infections Dec 18
SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Nov 08 SCYNEXIS, Inc. has filed a Follow-on Equity Offering in the amount of $50 million. Nov 07
SCYNEXIS, Inc. to Report Q3, 2024 Results on Oct 18, 2024 Oct 04
Second quarter 2024 earnings released: US$0.30 loss per share (vs US$2.56 profit in 2Q 2023) Aug 09
First quarter 2024 earnings released: EPS: US$0.009 (vs US$0.71 loss in 1Q 2023) May 09
New major risk - Revenue and earnings growth May 09
SCYNEXIS, Inc., Annual General Meeting, Jun 19, 2024 Apr 28
SCYNEXIS, Inc. to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases Apr 10
New major risk - Share price stability Apr 04
Full year 2023 earnings released: EPS: US$1.40 (vs US$1.47 loss in FY 2022) Mar 29
Bronstein, Gewirtz & Grossman LLC Announces SCYNEXIS, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit Jan 08
Third quarter 2023 earnings released: US$0.037 loss per share (vs US$0.62 loss in 3Q 2022) Nov 15
Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc Nov 10
Holzer & Holzer, LLC Announces Class Action Lawsuit Filed against SCYNEXIS, Inc Nov 09
SCYNEXIS, Inc. Presents New Preclinical Data on Second Generation Fungerp SCY-247 at the 11th Congress on Trends in Medical Mycology Oct 26
SCYNEXIS, Inc. Issues A Voluntary Nationwide Recall of BREXAFEMME® (Ibrexafungerp Tablets) Due to Potential for Cross Contamination with A Non-Antibacterial ß-Lactam Drug Substance Sep 28
Investor sentiment deteriorates as stock falls 33% Sep 25
Investor sentiment deteriorates as stock falls 16% Sep 08
New major risk - Revenue and earnings growth Aug 15
Second quarter 2023 earnings released: EPS: US$2.56 (vs US$0.31 loss in 2Q 2022) Aug 15
First quarter 2023 earnings released: US$0.71 loss per share (vs US$0.17 loss in 1Q 2022) May 12
Forecast breakeven date moved forward to 2023 Apr 02
Forecast to breakeven in 2025 Feb 28
Insufficient new directors Jan 10
Forecast to breakeven in 2025 Dec 31
Scynexis AnnouncesFDA Approval of Second Indication for Brexafemme® (Ibrexafungerp Tablets) for Reduction in Incidence of Recurrent Vulvovaginal Candidiasis Dec 02
Insufficient new directors Nov 23
SCYNEXIS, Inc. Announces Positive Results from Pooled Analysis of Two Phase 3 Studies (VANISH-303 and VANISH-306) in the Journal of Women’s Health Nov 04
SCYNEXIS, Inc. to Report Q3, 2022 Results on Nov 09, 2022 Nov 02
SCYNEXIS, Inc. Presents Positive Interim Data of Oral Ibrexafungerp for Severe Fungal Infections from Ongoing Phase 3 FURI Study During IDWeek 2022 Oct 25 SCYNEXIS, Inc. Announces CEO Changes
Insufficient new directors Oct 03
SCYNEXIS, Inc. Presents Positive Interim Data of ibrexafungerp for Refractory Candida Infections from Ongoing Phase 3 FURI Study Sep 09
Second quarter 2022 earnings released: US$0.31 loss per share (vs US$0.064 profit in 2Q 2021) Aug 16
SCYNEXIS, Inc. to Report Q2, 2022 Results on Aug 15, 2022 Aug 10
SCYNEXIS Presents Positive Data from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections During the 2022 IDSOG Annual Meeting Aug 06
SCYNEXIS, Inc. Announces U.S. Food and Drug Administration Acceptance and Priority Review of the Supplemental New Drug Application for BREXAFEMME Aug 02
Scynexis Presents Positive Data from Phase 3 Candle Nested Sub-Study Investigating Ibrexafungerp in Women with Recurrent Yeast Infections Who Failed Fluconazole During the Issvd Xxvi World Congress and International Vulvovaginal Disease Update Jul 20
Insufficient new directors Jul 19
Insufficient new directors Jun 29
Scynexis Announces Initiation of New Phase 3B Study (Vanquish) to Evaluate Oral Ibrexafungerp as A Treatment for Complicated Vulvovaginal Candidiasis (VVC) in Patients Who Failed to Respond to Treatment with Fluconazole Jun 24
SCYNEXIS, Inc. Announces Submission of Supplemental New Drug Application of BREXAFEMME® (ibrexafungerp tablets) to the U.S. Food and Drug Administration for an Expanded Indication for the Prevention of Recurrent Vaginal Yeast Infections Jun 09
SCYNEXIS, Inc., Annual General Meeting, Jun 16, 2022 May 13
SCYNEXIS, Inc. Presents New Interim Positive Data of Ibrexafungerp for Refractory Vulvovaginal Candidiasis from Ongoing Phase 3 FURI Study at the American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting May 12
SCYNEXIS, Inc. to Report Q1, 2022 Results on May 12, 2022 May 06
No longer forecast to breakeven Apr 27
Insufficient new directors Apr 27
SCYNEXIS, Inc. has completed a Follow-on Equity Offering in the amount of $44.988333 million. Apr 24
SCYNEXIS, Inc. Announces Positive Interim Data from its Ongoing Phase 3 FURI and CARES Studies Highlighting Oral Ibrexafungerp's Potency Against Severe Fungal Infections Apr 23
No longer forecast to breakeven Mar 31
SCYNEXIS Announces Positive Results from Its Pivotal Phase 3 CANDLE Study of Oral Ibrexafungerp for Prevention of Recurrent Vaginal Yeast Infections Feb 11
Insufficient new directors Feb 02
Forecast to breakeven in 2024 Jan 01
SCYNEXIS Announces Agreement with FDA on Innovative Strategy for Approval of Oral Ibrexafungerp for Treatment of Invasive Candidiasis Dec 07
Scynexis, Inc. Announces Peer-Reviewed Publication of Results Nov 24
Scynexis, Inc. Announces U.S. Availability of BREXAFEMME® Sep 24 Shareholder Returns 0L49 GB Pharmaceuticals GB Market 7D 0.07% 1.9% 0.8% 1Y -52.9% -2.8% 2.7%
See full shareholder returns
Return vs Market: 0L49 underperformed the UK Market which returned 2.7% over the past year.
Price Volatility Is 0L49's price volatile compared to industry and market? 0L49 volatility 0L49 Average Weekly Movement 6.6% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.7% 10% most volatile stocks in GB Market 10.4% 10% least volatile stocks in GB Market 2.6%
Stable Share Price: 0L49 has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: 0L49's weekly volatility (7%) has been stable over the past year.
About the Company SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company’s lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.
Show more SCYNEXIS, Inc. Fundamentals Summary How do SCYNEXIS's earnings and revenue compare to its market cap? 0L49 fundamental statistics Market cap US$37.92m Earnings (TTM ) -US$36.44m Revenue (TTM ) US$8.57m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 0L49 income statement (TTM ) Revenue US$8.57m Cost of Revenue US$14.68m Gross Profit -US$6.12m Other Expenses US$30.32m Earnings -US$36.44m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.96 Gross Margin -71.42% Net Profit Margin -425.41% Debt/Equity Ratio 22.6%
How did 0L49 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/29 17:54 End of Day Share Price 2024/12/27 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources SCYNEXIS, Inc. is covered by 14 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Jonathan Aschoff Brean Capital Jonathan Aschoff B. Riley Wealth Brian Kemp Dolliver Brookline Capital Markets
Show 11 more analysts 